UK Drug Payment Plan To Save £90m Yearly Progresses Through Parliament
Executive Summary
Legislation to align NHS statutory pricing scheme with the voluntary PPRS using a payment mechanism based on drug sales raises some industry concerns that it not be used simply as a sales tax. If it proceeds through Parliament as expected, it could take effect by mid-2017.
You may also be interested in...
UK Price Scheme Changes To Cost Pharmaceutical Industry £33m
The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.
ABPI Welcomes Amended Legislation On Curbing Excessive Unbranded Drug Prices
Newly passed UK legislation gives the government powers to curb pricing of unbranded generics when market forces fail. The Association of the British Pharmaceutical Industry has welcomed amendments to draft legislation that have addressed its concerns over onerous requirements.
Actavis UK’s ‘Excessive’ Price Hikes Targeted In Latest Competition Inquiry
The UK competition authority has provisionally found that Actavis UK imposed “excessive” price rises on its generic version of hydrocortisone for the life-threatening condition, adrenal insufficiency. The case has similarities to the price increases on phenytoin capsules, for which Pfizer and Flynn Pharma were recently fined.